Total Payments
$186,893
2024 Payments
$1,241
Companies
42
Transactions
394
Medicare Patients
4,565
Medicare Billing
$984,819
Payment Breakdown by Category
Other$122,360 (65.5%)
Research$41,884 (22.4%)
Travel$7,947 (4.3%)
Food & Beverage$7,393 (4.0%)
Consulting$6,798 (3.6%)
Education$511.95 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $117,587 | 76 | 62.9% |
| Unspecified | $41,884 | 25 | 22.4% |
| Travel and Lodging | $7,947 | 37 | 4.3% |
| Food and Beverage | $7,393 | 234 | 4.0% |
| Consulting Fee | $6,798 | 7 | 3.6% |
| Honoraria | $4,773 | 1 | 2.6% |
| Education | $511.95 | 14 | 0.3% |
Payments by Type
General
$145,010
369 transactions
Research
$41,884
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $45,642 | 42 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $42,182 | 76 | $0 (2024) |
| Gilead Sciences, Inc. | $30,184 | 14 | $0 (2019) |
| Relypsa, Inc. | $21,767 | 30 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,232 | 17 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $9,799 | 19 | $0 (2024) |
| Horizon Therapeutics plc | $6,762 | 20 | $0 (2022) |
| Keryx Biopharmaceuticals, Inc. | $5,557 | 4 | $0 (2018) |
| Retrophin, Inc. | $5,044 | 2 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $2,744 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,241 | 37 | Amgen Inc. ($229.90) |
| 2023 | $4,001 | 42 | Alexion Pharmaceuticals, Inc. ($2,644) |
| 2022 | $15,987 | 31 | Bayer HealthCare Pharmaceuticals Inc. ($9,034) |
| 2021 | $982.58 | 38 | Bayer HealthCare Pharmaceuticals Inc. ($156.66) |
| 2020 | $19,639 | 24 | Janssen Pharmaceuticals, Inc ($17,090) |
| 2019 | $60,219 | 55 | Gilead Sciences, Inc. ($30,155) |
| 2018 | $26,520 | 55 | Relypsa, Inc. ($13,302) |
| 2017 | $58,304 | 112 | AstraZeneca Pharmaceuticals LP ($39,767) |
All Payment Transactions
394 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Nephrology | ||||||
| 11/21/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $1.64 | General |
| Category: Nephrology | ||||||
| 11/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: NEPHROLOGY | ||||||
| 10/30/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $133.77 | General |
| Category: CRITICAL CARE | ||||||
| 10/23/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Nephrology | ||||||
| 10/09/2024 | NXSTAGE MEDICAL, INC. | NXSTAGE SYSTEM ONE (Device) | Food and Beverage | In-kind items and services | $87.94 | General |
| Category: Nephrology | ||||||
| 10/03/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: NEPHROLOGY | ||||||
| 09/17/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 09/17/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Nephrology | ||||||
| 09/04/2024 | CorMedix Inc. | DefenCath (Drug) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: Catheter Lock Solution | ||||||
| 08/30/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $179.25 | General |
| 08/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $23.69 | General |
| 08/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Cardio-renal | ||||||
| 08/26/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Diabetes | ||||||
| 08/06/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $7.17 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $40.03 | General |
| Category: Inflammation | ||||||
| 07/23/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 06/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $41.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/03/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $30.73 | General |
| Category: Inflammation | ||||||
| 05/30/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.51 | General |
| 05/22/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $1.68 | General |
| 05/09/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Hyperkalemia | ||||||
| 05/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $30,155 | 12 |
| Compass | Keryx Biopharmaceuticals, Inc. | $5,500 | 1 |
| 021FSGS16010 | Retrophin, Inc. | $5,000 | 1 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, | GlaxoSmithKline, LLC. | $1,229 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 885 | 7,263 | $456,170 | $189,564 |
| 2022 | 18 | 1,093 | 26,105 | $557,986 | $229,691 |
| 2021 | 13 | 1,275 | 2,359 | $538,250 | $252,457 |
| 2020 | 12 | 1,312 | 2,915 | $632,062 | $313,106 |
Total Patients
4,565
Total Services
38,642
Medicare Billing
$984,819
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 36 | 175 | $105,000 | $49,692 | 47.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 159 | 340 | $57,800 | $31,128 | 53.9% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 34 | 80 | $38,400 | $18,736 | 48.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 145 | 156 | $37,440 | $15,627 | 41.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 28 | 58 | $28,130 | $13,477 | 47.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 5,700 | $68,400 | $13,187 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 114 | 194 | $23,280 | $11,867 | 51.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 62 | 74 | $19,980 | $7,708 | 38.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 53 | 59 | $17,051 | $5,362 | 31.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 54 | 93 | $14,415 | $5,098 | 35.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $10,360 | $4,571 | 44.1% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 24 | 58 | $9,570 | $3,811 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 42 | $8,694 | $3,088 | 35.5% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 12 | 15 | $5,250 | $2,439 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 26 | $5,070 | $1,572 | 31.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 13 | 14 | $2,940 | $1,238 | 42.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 67 | $3,015 | $704.50 | 23.4% |
| 85018 | Blood count, hemoglobin | Office | 2023 | 18 | 65 | $520.00 | $134.56 | 25.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 19 | $855.00 | $123.76 | 14.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 263 | 675 | $114,939 | $53,102 | 46.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 60 | 146 | $87,600 | $39,887 | 45.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 113 | 154 | $41,580 | $20,648 | 49.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 172 | 188 | $45,120 | $19,387 | 43.0% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 16 | 71 | $34,080 | $16,527 | 48.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 19 | 18,750 | $42,188 | $14,890 | 35.3% |
About Dr. Ahmed Awad, DO
Dr. Ahmed Awad, DO is a Nephrology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740245182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ahmed Awad, DO has received a total of $186,893 in payments from pharmaceutical and medical device companies, with $1,241 received in 2024. These payments were reported across 394 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($117,587).
As a Medicare-enrolled provider, Awad has provided services to 4,565 Medicare beneficiaries, totaling 38,642 services with total Medicare billing of $984,819. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Kansas City, MO
- Active Since 04/19/2006
- Last Updated 09/15/2015
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1740245182
Products in Payments
- INVOKANA (Drug) $45,617
- FARXIGA (Drug) $41,858
- Veltassa (Drug) $21,814
- JARDIANCE (Drug) $10,802
- Kerendia (Drug) $9,799
- KRYSTEXXA (Biological) $6,816
- Auryxia (Drug) $5,782
- JYNARQUE (Drug) $1,283
- ULTOMIRIS (Biological) $1,260
- ACTHAR (Biological) $382.58
- RAYALDEE (Drug) $286.43
- Rayaldee (Drug) $278.88
- INVOS (Device) $263.20
- TAVNEOS (Drug) $176.90
- TERLIVAZ (Drug) $161.11
- INJECTAFER (Drug) $107.88
- NXSTAGE SYSTEM ONE (Device) $87.94
- Korsuva (Drug) $83.42
- Vafseo (Drug) $83.40
- TARPEYO (Drug) $82.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Kansas City
Dr. Richard Capling, D.o, D.O
Nephrology — Payments: $46,864
Nephrology $46,864
Dr. Tarek Darwish, Md, MD
Nephrology — Payments: $17,350
Nephrology $17,350
Aditi Gupta, M.d, M.D
Nephrology — Payments: $16,492
Nephrology $16,492
Dr. Alan Yu, M.b.,B.chir, M.B.,B.CHIR
Nephrology — Payments: $14,413
Nephrology $14,413
Ahmad Tuffaha, M.d, M.D
Nephrology — Payments: $12,646
Nephrology $12,646
Jignesh Shah, M.d, M.D
Nephrology — Payments: $7,445
Nephrology $7,445